The responsibilities of sponsors within the realm of decentralized clinical trials (DCTs) have been clearly outlined in the recently released draft guidance from the U.S. Food and Drug Administration (FDA). While the time-honored duties of sponsors remain unchanged in comparison with traditional brick-and-mortar clinical trials, the sponsoring of DCTs comes with added obligations.
As mentioned in the third edition of our blog series on DCTs by Foley & Lardner LLP, the FDA places additional emphasis on the proper coordination of decentralized activities, thoughtful accounting for data, and thorough compliance and protocol adherence in a DCT environment. The new responsibilities primarily revolve around ensuring these trials remain as controlled, reliable and as well-regulated as their traditional counterparts.
In the DCT environment, sponsors should keep in mind that there is a shift from centralized monitoring towards risk-based monitoring. This shift calls for a primary focus on critical study activities and data to identify, assess, monitor, and mitigate risks. Effective communication, strategic planning, and proactive risk management are crucial to the successful execution of DCTs.
The draft guidance is a vital roadmap for the future of clinical trials, outlining the new set of expectations, obligations, and compliance measures necessary to ensure the validity, integrity, safety, and potential of these trials. The increasingly adaptable, globalized, and patient-centric nature of DCTs make this guidance all the more necessary, establishing a framework for the trials of the future.
For a deeper understanding and full insight into the details regarding sponsor responsibilities in DCTs, consult the third edition of the blog series on DCTs, found at
Foley & Lardner LLP.